NIH PAR · NCI · K12
PAR-24-153: The NCI Worta McCaskill-Stevens Career Development Award for Community Oncology and Prevention Research (K12 Clinical Trial Optional)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
The purpose of the Worta McCaskill-Stevens K12 funding opportunity is to support institutional career development awards designed to prepare newly trained clinicians who have made a commitment to independent research careers in community oncology or cancer prevention, and to facilitate their transition to more advanced support mechanisms or independent research funding (e.g., K08, R03, R21, R01). The NOFO will allow the appointment of Scholars proposing to serve as the lead investigator of an independent community-based clinical trial; or proposing a separate ancillary study to an existing prevention, screening or control clinical trial; or proposing to gain research experience in a…
- NOFO number
- PAR-24-153
- Type
- PAR
- Activity code
- K12
- Primary institute
- NCI · National Cancer Institute
- Clinical trials
- Optional
- Posted
- Apr 19, 2024
- Opens
- May 18, 2024
- Expires
- Feb 19, 2027
PAR-24-153 due dates
No application due dates remain in the listed cycles. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| Letter of Intent Due Date(s) |
|---|
| Not Applicable |
| June 18, 2024 |
| June 18, 2024 |
| Not Applicable |
| November 2024 |
| January 2025 |
| April 2025 |
| February 19, 2025 |
| February 19, 2025 |
| Not Applicable |
| July 2025 |
| October 2025 |
| December 2025 |
| June 18, 2025 |
| June 18, 2025 |
| Not Applicable |
| November 2025 |
| January 2026 |
| April 2026 |
| February 18, 2026 |
| February 18, 2026 |
| Not Applicable |
| July 2026 |
| October 2026 |
Projects funded under PAR-24-153
NIH RePORTER lists 3 projects funded under PAR-24-153 in FY2022–FY2026, with $973K in award dollars. Counts include each project's later non-competing years, which keep the original NOFO number.
Projects funded
3
Distinct projects, FY2022–FY2026
New awards
3
Type 1 (new project) award records
NIH funding
$973K
Award dollars under PAR-24-153, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 1 | 1 | $54K |
| FY2026 | 3 | 2 | $919K |
Institutions with the most funding
- University of Maryland Baltimore$865K · 1 project
- Virginia Commonwealth University$54K · 1 project
- University of Tennessee Health Sci Ctr$54K · 1 project
Funding institutes
- NCI$973K · 4
Activity codes funded
- K124 records
Most recent new awards
- UTHSC K12 Career Development Program in Clinical Oncology (opens NIH RePORTER)
University of Tennessee Health Sci Ctr · 1K12CA300481-01A1 · NCI · Notice Jul 30, 2026
$54KK12
- The Massey/VCU’s McCaskill-Stevens K12 for Community Oncology and Prevention Research (opens NIH RePORTER)
Virginia Commonwealth University · 1K12CA300624-01A1 · NCI · Notice Apr 24, 2026
$54KK12
- Advancing Oncologic Research Communities in Health Equity (ARCH) K12 Program (opens NIH RePORTER)
University of Maryland Baltimore · 1K12CA301384-01 · NCI · Notice Sep 12, 2025
$54KK12
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
2 NIH institutes and offices take applications under PAR-24-153. Contact the program officer at the institute that fits your research before applying.
- NCI · National Cancer Institute
- none
Related notices
Mar 31, 2025
This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.
Apr 4, 2024 · NOT-OD-24-084
Overview of Grant Application and Review Changes for Due Dates on or after January 25, 2025. See Notice NOT-OD-24-084
Aug 23, 2023 · NOT-CA-23-081
Notice of Intent to Publish a Funding Opportunity for The NCI Worta McCaskill-Stevens Career Development Award for Community Oncology and Prevention Research K12 Clinical Trial Optional) See Notice NOT-CA-23-081
Award terms
- Application types allowed
- NewRenewalResubmission The OER Glossary and the How to Apply - Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO. Clinical Trial Optional: Accepting applications that either propose or do not propose clinical trial(s). Need help determining whether you are doing a clinical trial?
- Award budget
- Information
- Project period
- The project award duration for this funding opportunity may not exceed 5 years. Other
- Funds available and number of awards
- The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Companion NOFOs: PAR-22-136.
Other open NOFOs for K12
- PAR-27-025Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Not Allowed)NCI · next due Feb 12, 2027
- PAR-25-196Limited Competition: Mentored Research Career Development Program Award in Clinical and Translational Science Awards (CTSA) Program (K12 Clinical Trial Optional)NCATS · next due Jan 28, 2027
- PA-27-030Institutional Mentored Career Development Award (Parent K12) (Clinical Trials Not Allowed)OD · next due Feb 12, 2027
- PAR-24-089NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional)NIDA
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.